FDA promises quick review of Pfizer booster for all adults, CDC meets

(Reuters) -The U.S. Food and Drug Administration (FDA) said on Tuesday it would review Pfizer Inc (NYSE:)’s request to authorize booster doses of COVID-19 vaccine in all adults “as expeditiously as possible,” with the New York Times https://www.nytimes.com/2021/11/16/us/politics/fda-pfizer-booster-shots-adults.html?smid=tw-nytimes&smtyp=cur reporting that the regulatory nod could come as soon as Thursday.

The agency said it does not plan to hold a meeting of the outside experts on Pfizer’s request, concluding the request does not raise questions that would benefit from additional discussion by the members of the committee.

The decision from the FDA will likely come before a U.S. Centers for Disease Control and Prevention (CDC) advisory panel meets on Friday to discuss expanding the eligibility for booster doses of Pfizer/BioNTech’s vaccine, currently allowed for select groups of people.

Earlier this month, Pfizer had requested the FDA to authorize booster doses of the vaccine in all adults, presenting recent data showing the shot would help prevent disease across ages.

The company’s third dose has been authorized for immunocompromised individuals, people aged 65 and above, all those at high risk of severe disease, and people who are regularly exposed to the virus.

U.S. President Joe Biden’s administration in August announced plans to roll out booster doses for all adults in September.

The CDC sets U.S. adult and childhood immunization schedules based on recommendations from the Advisory Committee on Immunization Practices.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.